


PHASE 1 2017 – 2018 <i>Initiation: Literature Review</i>	PHASE 2 2019 – 2020 <i>Development: Qualitative</i>	PHASE 3 2020 – 2021 <i>Acquisition &amp; Data Reporting: Quantitative</i>	PHASE 4 2020 – 2021 <i>Activation: Data Gathering</i>	PHASE 5 2022+ <i>Application</i>
<b>OBJECTIVES</b>				
<ul style="list-style-type: none"> <li>Project planning including establishing a Scientific Advisory Board.</li> <li>Conduct global scientific literature review of patient reported impact outcomes (based on COSMIN criteria).</li> <li>Design GRIP: Global Reporting of Impacts on Patients - new research methodology.</li> <li>Publish results.</li> </ul>	<p><b>Qualitative Data:</b></p> <ul style="list-style-type: none"> <li>Identify list of items (impacts) associated with patients' dermatology conditions.</li> <li>Begin development of patient items and their statements.</li> <li>Initiate design of Phase 3 - Patient Data Verification Delphi.</li> </ul>	<p><b>Quantitative Data:</b></p> <ul style="list-style-type: none"> <li>Distribute two consecutive Delphi patient surveys to thousands (all continents) to validate data collected in Phase 2.</li> <li>Analyze results to refine the items and their statements.</li> <li>Begin development of PRIDD: Patient Reported Impact of Dermatological Diseases - new measurement tool.</li> <li>Publish results.</li> </ul>	<ul style="list-style-type: none"> <li>Delphi results integrated in to the development of PRIDD tool, and psychometric testing conducted.</li> <li>Launch PRIDD tool across all continents, for all conditions.</li> <li>Report scale development and peer review processes.</li> <li>Expand the PRIDD global dataset.</li> <li>Publish results.</li> </ul>	<ul style="list-style-type: none"> <li>Disseminate patient-impact dataset and share PRIDD tool worldwide.</li> <li>Promote more research and publications using PRIDD dataset and tool.</li> <li>Support patient organizations and educate other dermatology stakeholders and the public.</li> <li>Develop and launch local, regional and country level advocacy campaigns.</li> <li>Publish results.</li> </ul>
<b>OUTCOMES</b>				
<ul style="list-style-type: none"> <li>12,927 scientific articles reviewed.</li> <li>36 dermatology-specific patient-reported measures identified.</li> <li>No measure met Cosmin Category A criteria (i.e. none met gold standard).</li> </ul>	<ul style="list-style-type: none"> <li>Patient impact dataset enhanced and item statements analyzed in preparation for Phase 3.</li> <li>Poster sessions at conferences and GRIDD research paper(s) submitted for publication.</li> </ul>	<ul style="list-style-type: none"> <li>Items dataset richly enhanced due to thousands of patients who completed the global Delphi surveys.</li> <li>Refinements continue to be made to items and their statements in preparation for Phase 4.</li> <li>Poster sessions at conferences and GRIDD research paper(s) submitted for publication.</li> </ul>	<ul style="list-style-type: none"> <li>PRIDD tool successfully launched globally and recognized as superior measure that meets COSMIN Category A criteria.</li> <li>GRIDD open source PRIDD database established and promoted.</li> <li>Poster sessions at conferences and GRIDD research paper(s) submitted for publication.</li> </ul>	<ul style="list-style-type: none"> <li>Open source GRIDD data to:             <ul style="list-style-type: none"> <li>Produce publications and reports;</li> <li>Support advocacy;</li> <li>Improve public policy;</li> <li>Validate patients' voices.</li> </ul> </li> <li>Poster sessions at conferences and GRIDD research paper(s) submitted for publication.</li> </ul>



### BENEFITS of GRIDD

PATIENT ORGANIZATIONS	DATA & EVIDENCE	ADVOCACY & COMMUNICATIONS	GLOBAL DERMATOLOGY
<ul style="list-style-type: none"> <li>Access to dataset from PRIDD - World's first dermatology patient impact measurement tool.</li> <li>Evidence to support their missions and fundraising.</li> <li>Training, resources to support their work and in turn their patients.</li> <li>Patients' voice integrated in future decision-making.</li> </ul>	<ul style="list-style-type: none"> <li>Gap in patient-driven research now filled which will:             <ul style="list-style-type: none"> <li>Support publications and reports.</li> <li>Advance research employing the PRIDD patient impact measurement tool.</li> <li>Inform better public health policy.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Provide support for GlobalSkin's member campaigns to advance their priorities.</li> <li>Educate via global campaigns customized by disease and by country (i.e. language).</li> <li>Facilitate informed advocacy at local, regional and country levels to improve diagnosis, care and access to treatments.</li> </ul>	<ul style="list-style-type: none"> <li>Advocate internationally to raise awareness about the full impacts dermatological conditions have on patients.</li> <li>Build a more powerful, collaborative global network of dermatology stakeholders to work to fulfill shared objectives for better care and treatments for patients.</li> <li>Elevate the *Disability Adjusted Life Years (DALY) ranking for dermatology (used by the WHO for setting global health priorities).</li> </ul>